Physician profile
Michael T Ku
NPI 1497862650
$1,297.54
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $499 · 2024: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $466.94 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $198.66 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $141.93 | 2024 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.94 | 2023-2024 | Jardiance |
| Abbvie INC. | $111.29 | 2023-2024 | |
| Astellas Pharma US INC | $40.67 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $38.73 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $33.27 | 2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Exact Sciences Corporation | $29.81 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $26.37 | 2023 | |
| Phathom Pharmaceuticals, INC. | $20.95 | 2024 | Voquezna |
| Phadia US INC. | $19.55 | 2023 | Immunocap |
| Amgen INC. | $17.44 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $15.76 | 2024 | Zepbound, Jardiance |
| Tolmar, INC. | $13.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.